Inivata is leading the liquid biopsy revolution and transforming the lives of cancer patients.
Inivata is a leader in liquid biopsy
Our technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and reinforced by multiple high calibre publications. Our lead product, InVisionFirst®-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients.
Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and our wider platform, which is applicable to a range of cancer types.
We have a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC, USA and R&D laboratories in Cambridge, UK.
Our Liquid Biopsy Platform and Genomic Tests
Using a simple blood draw, ctDNA analysis is a new tool for oncologists to detect cancer, stratify patients, and monitor individual response to treatment.
A non-invasive liquid biopsy offers a revolution in how cancer is detected, monitored and treated, providing the potential for frequent tumor profiling and a more personalized approach to cancer care.
Inivata works with leading industry and academic researchers to develop new clinical applications for liquid biopsy and ctDNA analysis.
Our ambition is to provide genuine and practical benefits to the healthcare industry, from physicians and patients, to pharmaceutical companies and payers.
Our achievements would not be possible without the outstanding team that make up Inivata.
Working at Inivata
We recognize the value of working together as a team, towards a common goal. As a team, our people help to shape the vision, culture, and direction of our company.
We aim to provide the highest standards of training and development, so that people working here are given the opportunity to advance their careers, as we look forward together to advance clinical outcomes and patient care. We provide a rewarding working environment, to accomplish great things, and to help cancer patients and their families.
Inivata's investors and shareholders include: